Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/375"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:content |
"The FDA recommends warfarin as a preferred CYP2D6 substrate for in vivo studies in it most recent guidance document (See Table 2, p. 19) and expressly mentions that S-warfarin should be target of chemical analysis on 9, 1st paragraph."
|
| dc:creator | |
| dc:date |
"09/24/2009 15:39:40"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ S-warfarin_primary_total_clearance_enzyme_cyp2c9, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1656 }